News

Registration Now Open for the 2026 Annual Scientific Meeting

by | February 3, 2026 | Sin categorizar | 0 Comments

Registration is now open for the ALIPANC Annual Scientific Meeting, which will take place on March 13, 2026, at Hospital Universitario HM Sanchinarro (Madrid). Registrations: https://form.jotform.com/260221905533348 The Call for Abstracts is also open and will be...
Read more

CNIO Seminar: Dr. Florencia McAllister – “Cancer as an ecosystem: how microbes shape tumors”.

by | January 23, 2026 | Sin categorizar | 0 Comments

We are pleased to announce an upcoming seminar of special interest to the pancreatic cancer research community. On Friday, January 23, at 12:00 noon (CET), Dr. Florencia McAllister, M.D., Associate Professor of Clinical Cancer Prevention and Gastrointestinal Medical...
Read more

ALIPANC researchers conducted a study that links venous thromboembolic disease (VTE) with poorer survival in pancreatic cancer patients

by | January 14, 2026 | Sin categorizar | 0 Comments

The group led by Andrés Muñoz (Gregorio Marañón Hospital, Madrid) has published a subanalysis of the ONCOTHROMB12-01 study, which examines the impact of a diagnosis of venous thromboembolic disease (VTE) on the overall survival of cancer patients. A diagnosis of VTE...
Read more

Pancreatic Cancer Conference, London 2026 – Cancer Research UK

by | December 19, 2025 | Sin categorizar | 0 Comments

Registration is now open for the Pancreatic Cancer Conference organised by Cancer Research UK. The event will take place in London from 7–9 July....
Read more

ALPANC researchers publish study protocol comparing 3D modeling versus conventional CT

by | December 17, 2025 | Sin categorizar | 0 Comments

3D-PANC study protocol: Is three-dimensional imaging technology superior to computed tomography for assessing the response to neoadjuvant treatment in patients with borderline or locally advanced pancreatic adenocarcinoma? This study focuses on improving the...
Read more

New potential therapeutic target for pancreatic cancer identified by ALIPANC researchers

by | December 16, 2025 | Sin categorizar | 0 Comments

The study by Parejo-Alonso et al. identifies PPAR-δ as a critical transcription factor mediating pancreatic cancer cell adaptation to microenvironmental stress. Normally involved in lipid metabolism, PPAR-δ is overexpressed in pancreatic tumors and, under metabolic...
Read more

ALIPANC researchers develop a new therapeutic combination in preclinical models of pancreatic cancer.

by | December 16, 2025 | Sin categorizar | 0 Comments

This study conducted by researchers from Vigo presents an innovative sequential therapeutic strategy against pancreatic ductal adenocarcinoma, one of the most lethal cancers due to its stromal barrier that prevents drug penetration. The novelty lies in the biphasic...
Read more

Merry Christmas!

by | December 15, 2025 | Sin categorizar | 0 Comments

Read more

GNAS-ddPCR: A Cost-Effective First Step in the Diagnosis of Pancreatic Cystic Neoplasms, Developed by Researchers from the ALIPANC Group

by | December 10, 2025 | Sin categorizar | 0 Comments

The analysis of GNAS mutations using ddPCR in fluid obtained through endoscopic ultrasound–guided fine-needle aspiration has proven to be a useful and cost-effective diagnostic tool for evaluating mucinous pancreatic cystic neoplasms. This technique can be applied...
Read more

Researchers from ALIPANC describe a triple therapy targeting key proteins in KRAS signaling that induces complete tumor regression in a mouse model

by | December 10, 2025 | Sin categorizar | 0 Comments

A study led by the Experimental Oncology Group at the Spanish National Cancer Research Centre (CNIO) has described a triple-combination therapy for pancreatic cancer. The work has been published in the prestigious journal Proceedings of the National Academy of...
Read more